Palonosetron, second generation 5-HT3 antagonist: a new perspective in CINV management. Hematol Meeting Rep [Internet]. 2009 Jun. 8 [cited 2025 Jun. 20];2(7). Available from: https://journals.pagepress.org/hmr/article/view/414